10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00885612 |
Recruitment Status
:
Completed
First Posted
: April 22, 2009
Last Update Posted
: June 29, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Breast Cancer |
Study Type : | Observational |
Actual Enrollment : | 1114 participants |
Observational Model: | Case-Only |
Time Perspective: | Cross-Sectional |
Official Title: | 10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors |
Study Start Date : | May 2009 |
Actual Primary Completion Date : | March 2010 |
Actual Study Completion Date : | March 2010 |

- The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment. [ Time Frame: 1 visit ]
- To describe 10-year CHD risk comparing to the historical data of 10-year cancer-specific mortality in breast cancer [ Time Frame: 1 Visit ]
- To analyse CHD management patterns according to defined 10-year CHD risk categories [ Time Frame: 1 Visit ]
- To describe correlation between concommitant medication(Anthracycline, Trasuzumab) and CHD risk [ Time Frame: 1 Visit ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Early Breast Cancer patients
- Postmenopausal Status
- patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months
Exclusion Criteria:
- Advanced Breast Cancer patients(stage iii, iv)
- Patients who are hard to be analysed by limitation of chart record according to investigators discretion
- patients who already have been registered in this study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00885612
Korea, Republic of | |
Research Site | |
Cheonan, Chungcheongnam-do, Korea, Republic of | |
Research Site | |
Chuncheon, Gangwon-do, Korea, Republic of | |
Research Site | |
Goyang-si, Gyeonggi-do, Korea, Republic of | |
Research Site | |
Seongnam-si, Gyeonggi-do, Korea, Republic of | |
Research Site | |
Pohang, Gyeongsangbuk-do, Korea, Republic of | |
Research Site | |
Masan-si, Gyeongsangnam-do, Korea, Republic of | |
Research Site | |
Anyang, Korea, Republic of | |
Research Site | |
Busan, Korea, Republic of | |
Research Site | |
Chunan, Korea, Republic of | |
Research Site | |
DaeGu, Korea, Republic of | |
Research Site | |
Daejeon, Korea, Republic of | |
Research Site | |
Daejon, Korea, Republic of | |
Research Site | |
GuangJu, Korea, Republic of | |
Research Site | |
Gwangju, Korea, Republic of | |
Research Site | |
Incheon, Korea, Republic of | |
Research Site | |
Inchon, Korea, Republic of | |
Research Site | |
Jeonju, Korea, Republic of | |
Research Site | |
Kangnung, Korea, Republic of | |
Research Site | |
Koyang, Korea, Republic of | |
Research Site | |
Kyunggi, Korea, Republic of | |
Research Site | |
Pusan, Korea, Republic of | |
Research Site | |
Seoul(Kangbuk), Korea, Republic of | |
Research Site | |
Seoul(Kangdong), Korea, Republic of | |
Research Site | |
Seoul(Kangnam), Korea, Republic of | |
Research Site | |
Seoul(Yeouido), Korea, Republic of | |
Research Site | |
Seoul, Korea, Republic of | |
Research Site | |
Suwon, Korea, Republic of | |
Research Site | |
Ulsan, Korea, Republic of |
Study Director: | JoonWoo Bahn, MD, PhD | AstraZeneca Korea |
Responsible Party: | MC MD, AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00885612 History of Changes |
Other Study ID Numbers: |
NIS-OKR-DUM-2009/1 |
First Posted: | April 22, 2009 Key Record Dates |
Last Update Posted: | June 29, 2010 |
Last Verified: | June 2010 |
Keywords provided by AstraZeneca:
CHD-Risk Breast Cancer Aromatase Inhibitors postmenopausal early breast cancer |
Additional relevant MeSH terms:
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Aromatase Inhibitors Steroid Synthesis Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |